Leaflet: information for the user
DulcoLax Bisacodilo 10 mg suppositories
Bisacodilo
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Follow exactly the administration instructions contained in this leaflet or those given by your doctor or pharmacist.
The bisacodyl, active ingredient of this medication, belongs to the group of stimulant laxatives, which act by direct contact with the intestinal mucosa, stimulating the intestinal wall nerve endings, thereby increasing its motility.
It is indicated for symptomatic relief of occasional constipation in adults, adolescents, and children over 10 years old.
Consult a doctor if it worsens or does not improve after 7 days of treatment.
Do not use DulcoLax:
Warnings and precautions
Consult your doctor or pharmacist before starting to use DulcoLax:
Children and adolescents
Children under 10 years old cannot use this medication.
Use of DulcoLax with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
In particular, if you are using any of the following medications, it may be necessary to interrupt treatment or modify the dose of one of them:
Interference with diagnostic tests:
Use of DulcoLax with food and beverages
Do not take licorice while using this medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
During the use of this type of laxative due to a vasovagal response (e.g. abdominal spasms) you may experience dizziness and/or syncope. If you experience abdominal spasms, you should avoid potentially hazardous tasks such as driving or operating machinery.
Follow exactly the administration instructions for this medication contained in this leaflet or those indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose in adults is:
1 suppository (10 mg of bisacodyl).
This medication is administered rectally.
It must be unfolded and inserted into the rectum through the pointed part.
The effect usually appears within 20 minutes of administration (between 10 and 30 minutes).
If symptoms worsen, if no bowel movement occurs after 12 hours or if symptoms persist after 7 days of treatment, you must consult your doctor.
Use in children and adolescents
Adolescents and children over 10 years old
The recommended dose is 1 suppository (10 mg of bisacodyl)
Children under 10 years old cannot use this medication as it contains 10 mg of bisacodyl.
If you use more DulcoLax than you should
If you have used more DulcoLax than you should, consult your doctor or pharmacist immediately.
The most frequent symptoms of overdose are: abdominal cramps, vomiting, mucous and diarrheal stools, and loss of fluid, potassium, and other electrolytes, fatigue or weakness.
Treatment in these cases will consist of stopping the use of the laxative and subsequent rehydration with saline solution, liquids, and administration of mineral salts.These measures are especially important in the elderly and young.
In case of overdose or accidental ingestion, visit your doctor or call the Toxicological Information Service (phone: 91 562 04 20), indicating the medication and the amount ingested.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
During the period of use of medications with bisacodilo, the following adverse effects have been observed, whose frequency has not been established with precision. The most frequent adverse effects are abdominal pain and diarrhea. The following may occur: abdominal discomfort, anorectal discomfort, digestive alterations such as abdominal pain or cramps (which may be associated with nausea and/or vomiting), bloody stools (hematochezia), flatulence, abdominal distension, slower intestinal movement, and colitis. Less frequently, allergic reactions, skin eruptions, dehydration, and swelling of the face, lips, mouth, tongue, or throat that may cause difficulty swallowing or breathing (angioedema) may also occur.
The use of medications with bisacodilo, the active principle of this medication, over long periods of time may cause an increase in water loss, potassium salts, and other salts. This may lead to cardiac function alterations, muscle weakness, and fatigue, particularly if administered at the same time as diuretics and corticosteroids.
In addition, cases of dizziness and syncope have been reported. Dizziness and syncope that appear after taking medications with bisacodilo may be due to a vasovagal response (e.g., abdominal spasms, defecation).
Reporting Adverse Effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 86°F (30°C).
Expiration Date
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection point at your pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of DulcoLax
Appearance of the product and contents of the packaging
DulcoLax are yellowish white suppositories.
They are presented in packaging containing an aluminum blister of 6 or 12 suppositories.
Holder of the marketing authorization:
Opella Healthcare Spain, S.L.
C/Rosselló i Porcel, 21
08016 – Barcelona
Spain
Sanofi Group
Responsible for manufacturing:
Istituto de Angeli, S.r.l.
Località Prulli, 103/C
50066 Reggello (Florence).
Italy
Date of the last review of this leaflet:October 2019
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.